29:
640:
636:
432:
for "Study
Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)" at
295:
579:
379:. In rat models and human clinical trials of NASH it has been shown to reduce fibrosis and steatosis, and in human clinical trials of PSC it improved cholestasis and reduced markers of liver injury.
337:
InChI=InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36)
41:
593:
Patel K, Harrison SA, Elkhashab M, et al. (9 Jan 2021). "Cilofexor, a
Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial".
637:"Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)"
575:
505:"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis"
309:
660:
411:
for "Safety, Tolerability, and
Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)" at
670:
364:
329:
65:
559:
for "Safety, Tolerability, and
Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS)" at
675:
368:
187:
451:"The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model"
690:
136:
216:
127:
360:
685:
82:
665:
618:
560:
434:
412:
680:
610:
536:
482:
176:
91:
602:
526:
516:
472:
462:
232:
196:
383:
531:
504:
477:
450:
654:
622:
116:
317:
C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CN(C5)C6=NC=CC(=C6)C(=O)O)O)Cl
555:
428:
407:
467:
376:
372:
271:
167:
614:
540:
486:
20:
147:
102:
606:
521:
28:
371:(PSC). It is being investigated for use alone or in combination with
207:
503:
Trauner M, Gulamhusein A, Hameed B, et al. (19 January 2019).
156:
73:
2-methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid
294:
285:
576:"Gilead and Novo Nordisk Expand NASH Clinical Collaboration"
449:
Schwabl P, Hambruch E, Budas GR, et al. (9 Jan 2021).
363:(FXR) agonist in clinical trials for the treatment of
382:
It is being developed by the pharmaceutical company
367:(NAFLD), non-alcoholic steatohepatitis (NASH), and
283:
270:
231:
226:
206:
186:
166:
146:
135:
126:
101:
81:
56:
40:
35:
115:
90:
498:
496:
444:
442:
422:
420:
401:
399:
8:
19:
570:
568:
175:
530:
520:
476:
466:
195:
639:(Press release). Gilead. 18 March 2021.
578:(Press release). Gilead. 18 March 2021.
395:
334:
314:
155:
70:
18:
215:
7:
106:
14:
365:non-alcoholic fatty liver disease
643:from the original on 2022-01-21.
582:from the original on 2022-01-20.
255:
249:
243:
27:
342:Key:KZSKGLFYQAYZCO-UHFFFAOYSA-N
661:Drugs not assigned an ATC code
369:primary sclerosing cholangitis
261:
237:
1:
468:10.3390/biomedicines9010060
707:
227:Chemical and physical data
671:Chlorobenzene derivatives
325:
305:
61:
26:
16:Drug in clinical trials
553:Clinical trial number
426:Clinical trial number
405:Clinical trial number
676:Cyclopropyl compounds
361:farnesoid X receptor
359:) is a nonsteroidal
23:
561:ClinicalTrials.gov
435:ClinicalTrials.gov
413:ClinicalTrials.gov
375:, selonsertib, or
607:10.1002/hep.31205
522:10.1002/hep.30509
350:
349:
296:Interactive image
698:
691:Carboxylic acids
645:
644:
633:
627:
626:
590:
584:
583:
572:
563:
551:
545:
544:
534:
524:
500:
491:
490:
480:
470:
446:
437:
424:
415:
403:
298:
278:
263:
257:
251:
245:
239:
219:
199:
179:
159:
139:
119:
109:
108:
94:
31:
24:
22:
706:
705:
701:
700:
699:
697:
696:
695:
651:
650:
649:
648:
635:
634:
630:
592:
591:
587:
574:
573:
566:
552:
548:
502:
501:
494:
448:
447:
440:
425:
418:
404:
397:
392:
384:Gilead Sciences
355:(also known as
346:
343:
338:
333:
332:
321:
318:
313:
312:
301:
276:
266:
260:
254:
248:
242:
222:
202:
182:
162:
142:
122:
105:
97:
77:
74:
69:
68:
52:
17:
12:
11:
5:
704:
702:
694:
693:
688:
683:
678:
673:
668:
663:
653:
652:
647:
646:
628:
585:
564:
546:
515:(3): 788–801.
492:
438:
416:
394:
393:
391:
388:
348:
347:
345:
344:
341:
339:
336:
328:
327:
326:
323:
322:
320:
319:
316:
308:
307:
306:
303:
302:
300:
299:
291:
289:
281:
280:
274:
268:
267:
264:
258:
252:
246:
240:
235:
229:
228:
224:
223:
221:
220:
212:
210:
204:
203:
201:
200:
192:
190:
184:
183:
181:
180:
172:
170:
164:
163:
161:
160:
157:15168 DB 15168
152:
150:
144:
143:
141:
140:
132:
130:
124:
123:
121:
120:
112:
110:
99:
98:
96:
95:
87:
85:
79:
78:
76:
75:
72:
64:
63:
62:
59:
58:
54:
53:
51:
50:
46:
44:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
703:
692:
689:
687:
684:
682:
679:
677:
674:
672:
669:
667:
664:
662:
659:
658:
656:
642:
638:
632:
629:
624:
620:
616:
612:
608:
604:
600:
596:
589:
586:
581:
577:
571:
569:
565:
562:
558:
557:
550:
547:
542:
538:
533:
528:
523:
518:
514:
510:
506:
499:
497:
493:
488:
484:
479:
474:
469:
464:
460:
456:
452:
445:
443:
439:
436:
431:
430:
423:
421:
417:
414:
410:
409:
402:
400:
396:
389:
387:
385:
380:
378:
374:
370:
366:
362:
358:
354:
340:
335:
331:
324:
315:
311:
304:
297:
293:
292:
290:
287:
282:
275:
273:
269:
236:
234:
230:
225:
218:
217:ChEMBL4297613
214:
213:
211:
209:
205:
198:
194:
193:
191:
189:
185:
178:
174:
173:
171:
169:
165:
158:
154:
153:
151:
149:
145:
138:
134:
133:
131:
129:
125:
118:
114:
113:
111:
104:
100:
93:
89:
88:
86:
84:
80:
71:
67:
60:
55:
48:
47:
45:
43:
39:
36:Clinical data
34:
30:
25:
631:
601:(1): 58–71.
598:
594:
588:
554:
549:
512:
508:
458:
455:Biomedicines
454:
427:
406:
381:
356:
352:
351:
92:1418274-28-8
556:NCT03890120
429:NCT04971785
408:NCT02781584
377:semaglutide
373:firsocostat
279: g·mol
57:Identifiers
686:Azetidines
655:Categories
595:Hepatology
509:Hepatology
390:References
284:3D model (
272:Molar mass
197:YUN2306954
168:ChemSpider
128:IUPHAR/BPS
83:CAS Number
66:IUPAC name
666:Pyridines
623:211727006
461:(1): 60.
353:Cilofexor
21:Cilofexor
681:Oxazoles
641:Archived
615:32115759
580:Archived
541:30661255
487:33435509
177:68007315
148:DrugBank
117:71228883
42:ATC code
532:6767458
478:7827357
357:GS-9674
233:Formula
103:PubChem
621:
613:
539:
529:
485:
475:
310:SMILES
277:586.85
208:ChEMBL
619:S2CID
330:InChI
286:JSmol
137:10644
611:PMID
537:PMID
483:PMID
188:UNII
49:None
603:doi
527:PMC
517:doi
473:PMC
463:doi
107:CID
657::
617:.
609:.
599:72
597:.
567:^
535:.
525:.
513:70
511:.
507:.
495:^
481:.
471:.
457:.
453:.
441:^
419:^
398:^
386:.
250:Cl
247:22
241:28
625:.
605::
543:.
519::
489:.
465::
459:9
288:)
265:5
262:O
259:3
256:N
253:3
244:H
238:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
